相似文献
1
Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials.随机试验中用于预防或治疗新型冠状病毒肺炎的脂质调节药物
medRxiv. 2021 May 4:2021.05.03.21256468. doi: 10.1101/2021.05.03.21256468.
2
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.探讨用于预防或治疗 COVID-19 的调脂药物：《美国心脏病学会杂志》最新综述。
J Am Coll Cardiol. 2021 Oct 19;78(16):1635-1654. doi: 10.1016/j.jacc.2021.08.021.
3
Nonstatin therapies for management of dyslipidemia: a review.用于血脂异常管理的非他汀类疗法：综述
Clin Ther. 2015 Oct 1;37(10):2153-79. doi: 10.1016/j.clinthera.2015.09.001. Epub 2015 Sep 26.
4
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?混合性血脂异常的优化管理：他汀类药物单一疗法之后我们还有什么？
Adv Cardiol. 2008;45:127-153. doi: 10.1159/000115192.
5
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.在管理式医疗环境中，以低高密度脂蛋白胆固醇为靶点降低残余心血管风险。
J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1.
6
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.甘油三酯、动脉粥样硬化与心血管结局研究：聚焦于ω-3脂肪酸
Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7.
7
Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.长链ω-3脂肪酸、贝特类药物和烟酸作为高甘油三酯血症治疗的治疗选择：文献综述
Atherosclerosis. 2015 Oct;242(2):647-56. doi: 10.1016/j.atherosclerosis.2015.06.012. Epub 2015 Jun 11.
8
Lipid-lowering agents for nephrotic syndrome.用于肾病综合征的降脂药物。
Cochrane Database Syst Rev. 2013 Dec 10;2013(12):CD005425. doi: 10.1002/14651858.CD005425.pub2.
9
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).烟酸在升高高密度脂蛋白胆固醇以降低动脉粥样硬化性心血管疾病患者心血管事件方面的作用，以及最佳治疗后的低密度脂蛋白胆固醇。 理由和研究设计。代谢综合征伴低 HDL/高甘油三酯患者中的动脉血栓形成干预：对全球健康结局的影响（AIM-HIGH）。
Am Heart J. 2011 Mar;161(3):471-477.e2. doi: 10.1016/j.ahj.2010.11.017. Epub 2011 Feb 2.
10
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.管理他汀类药物治疗患者与高密度脂蛋白胆固醇和甘油三酯相关的残余心血管疾病风险：临床更新。
Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9.
Zotero 插件